Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy

BACKGROUND: In clinical trials of pegloticase, a PEGylated uricase developed for treatment of gout refractory to conventional therapy, infusion-related reactions (IRs) were the second most frequent adverse event reported. OBJECTIVE: The objective of this study was to provide a detailed account of IR...

Descripción completa

Detalles Bibliográficos
Autores principales: Baraf, Herbert S. B., Yood, Robert A., Ottery, Faith D., Sundy, John S., Becker, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280274/
https://www.ncbi.nlm.nih.gov/pubmed/25417679
http://dx.doi.org/10.1097/RHU.0000000000000200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280274/
https://www.ncbi.nlm.nih.gov/pubmed/25417679
http://dx.doi.org/10.1097/RHU.0000000000000200

Ejemplares similares